Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study

INTRODUCTION: This study explored the efficacy and safety of a serotonin‐6 receptor antagonist, masupirdine, as adjunct treatment in patients with moderate Alzheimer's disease (AD) concomitantly treated with donepezil and memantine. METHODS: The effects of masupirdine were evaluated in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Nirogi, Ramakrishna, Ieni, John, Goyal, Vinod Kumar, Ravula, Jyothsna, Jetta, Satish, Shinde, Anil, Jayarajan, Pradeep, Benade, Vijay, Palacharla, Veera Raghava Chowdary, Dogiparti, Dhanunjay Kumar, Jasti, Venkat, Atri, Alireza, Cummings, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157584/
https://www.ncbi.nlm.nih.gov/pubmed/35662833
http://dx.doi.org/10.1002/trc2.12307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157584/
https://www.ncbi.nlm.nih.gov/pubmed/35662833
http://dx.doi.org/10.1002/trc2.12307

Ejemplares similares